Scientists Identify a Possible Biological Link Between Obesity and Alzheimer’s
Key Takeaways:
- Researchers at Houston Methodist have identified phosphatidylethanolamines (PEs) – a class of fat molecule found in cell membranes – as a possible biological link between obesity and Alzheimer’s disease.
- Obesity appears to increase levels of these molecules in body tissue, after which they are packaged into tiny particles that travel to the brain, disrupting communication between brain cells, weakening immune protection and encouraging amyloid proteins to accumulate.
- Restoring a healthier balance of PEs reduced disruption in lipid regulation and improved brain function and cognitive performance in models of Alzheimer’s disease, pointing to a possible target for future treatments.
Why researchers are looking beyond the brain
Alzheimer’s disease has long been studied as a condition of the brain itself, defined by the amyloid plaques and tangles found in brain tissue. A growing body of research, however, suggests that the disease may be influenced by biological changes taking place far beyond the skull. Metabolic health – and obesity in particular – is now emerging as a possible contributor to the processes that worsen the disease.
New findings from Houston Methodist add weight to that idea. The study examined how changes in body fat associated with obesity may send damaging signals to the brain, where they appear to interfere with the brain’s immune system and contribute to the biological damage linked to Alzheimer’s disease.
The team behind the study
The research was co-led by Stephen Wong, Ph.D., the John S. Dunn Presidential Distinguished Chair in Biomedical Engineering, and Li Yang, Ph.D., a research associate in the Chao Center for BRAIN at Houston Methodist. The findings were published in the journal Molecular Neurodegeneration.
Fat molecules may connect obesity and Alzheimer’s disease
At the centre of the work is a class of lipid, or fat molecule, called phosphatidylethanolamines, abbreviated to PEs. These molecules are found in cell membranes throughout the body, where they form part of the basic structure of every cell.
According to the study, obesity raises the amount of these molecules in body tissue. The PEs are then loaded into tiny particles that are capable of travelling through the body and reaching the brain – effectively carrying a metabolic signal from fat tissue to the central nervous system.
What happens once these particles reach the brain
Once inside the brain, these particles appear to do three things at once. They can interfere with communication between brain cells, they can weaken immune protection, and they can encourage amyloid proteins to accumulate. Amyloid buildup is one of the major biological features associated with Alzheimer’s disease.
That combination matters, because it suggests obesity is not simply sitting alongside Alzheimer’s risk as a separate problem, but may be actively feeding into the mechanisms that drive the disease.
“Obesity can change how signals travel to the brain,” Wong said. “The good news is that this may be something we can treat. Instead of looking at Alzheimer’s risk tied to obesity as just a metabolic problem, this research suggests we may be able to target the process that connects those changes to the brain.”
Restoring lipid balance improved brain function
The findings also suggest a possible direction for future treatments. When the researchers restored a healthier balance of PEs, they observed less disruption in lipid regulation.
Correcting the imbalance also improved brain function and cognitive performance in models of Alzheimer’s disease. Cognitive performance refers to abilities such as learning, memory, attention and problem solving – the domains most visibly affected as Alzheimer’s progresses.
Taken together, these results suggest that targeting the fat molecules themselves, or the pathway that carries them to the brain, could potentially reduce some of the damage associated with obesity and Alzheimer’s disease.
A growing public health challenge
The stakes are considerable. According to the Centers for Disease Control and Prevention, more than 6.5 million Americans are living with Alzheimer’s disease. That total is expected to rise to nearly 14 million by 2060.
Yang emphasised that a good deal more research will be required before treatments aimed at PEs can be tested as prevention or therapy in people. Even so, the findings introduce a possible strategy for intervening earlier in individuals whose metabolic health may place them at greater risk of Alzheimer’s disease.
What this may mean for practice
For healthcare professionals, work of this kind reinforces a message that has been building across obesity research for some years: excess weight is bound up with a wide range of downstream conditions through complex biological pathways, rather than existing in isolation. Understanding those pathways – and being able to discuss them sensitively with patients – is increasingly part of everyday clinical conversation. CCH’s Obesity Essentials CPD short course is designed with exactly that in mind, introducing the many factors that cause and contribute to obesity alongside the practical skills needed to assess and support people living with overweight and obesity.
It is worth being clear about the limits of the current evidence. The results described here come from laboratory models rather than clinical trials in people, and no PE-targeted treatment is close to being available. What the study offers is a plausible mechanism and a candidate target – both of which are needed before prevention strategies aimed at metabolic risk can be tested properly.
Study collaborators and funding
Other collaborators on the study include Li Yang, Jianting Sheng, Shaohua Qi, Zheng Yin, Michael Chan, Yuliang Cao, Hong Zhao, Zhihao Wan, Bill Chan, Ju Ahn, Xiaohui Yu, Matthew Vasquez and Shan Xu from Houston Methodist; Xianlin Han from the University of Texas, San Antonio; Weiming Xia from Boston University; and Willa Hsueh from Ohio State University.
The study was funded by grants from the Cure Alzheimer’s Fund, the T.T. and W.F. Chao Foundation, and the John S. Dunn Research Foundation.
CCH insight
Research linking obesity to conditions well beyond metabolic health is reshaping how clinicians talk to patients about weight. CCH’s Obesity Essentials online CPD short course gives healthcare professionals the knowledge and confidence to assess and manage overweight and obesity effectively, and to hold those conversations with compassion and clarity. The course takes 8–10 hours, is completed entirely online at your own pace, and carries 10 CPD hours plus a certificate of completion.
Read More
New AI Tool Pinpoints Genes and Drug Combinations That Restore Health in Diseased Cells
Key Takeaways:
- Harvard researchers have developed PDGrapher, an AI tool that identifies genes and drug combinations most likely to restore diseased cells to a healthy state.
- The model uses graph neural networks to map cellular relationships and predict effective single or combined drug targets, significantly reducing the need for exhaustive drug screening.
- PDGrapher demonstrated high accuracy and speed across multiple cancer datasets, offering promise for personalised medicine and drug discovery in complex diseases such as cancer, Parkinson’s, and Alzheimer’s.
Introduction: A new era in drug discovery
Researchers at Harvard Medical School (HMS) have unveiled a powerful artificial intelligence (AI) model capable of identifying therapies that can reverse disease at the cellular level. This innovation, published in Nature Biomedical Engineering on 9 September, could reshape how new drugs are discovered, designed, and personalised for patients.
Unlike traditional approaches that examine one protein target or drug candidate at a time, this new model — named PDGrapher and freely available to researchers — analyses multiple cellular drivers of disease. It identifies the genes most likely to return diseased cells to normal function and pinpoints the most promising single or combined drug targets to correct the underlying cellular dysfunction.
“Traditional drug discovery resembles tasting hundreds of prepared dishes to find one that happens to taste perfect,” explained senior study author Marinka Zitnik, Associate Professor of Biomedical Informatics at HMS’s Blavatnik Institute. “PDGrapher works like a master chef who understands what they want the dish to be and exactly how to combine ingredients to achieve the desired flavour.”
Limitations of traditional drug discovery
Historically, drug discovery has focused on activating or inhibiting a single protein target. This approach has produced successful therapies such as kinase inhibitors, which block proteins that drive cancer cell growth. However, Zitnik emphasised that such strategies often fall short for diseases driven by multiple interacting pathways and genes.
She noted that many recent therapeutic breakthroughs — including immune checkpoint inhibitors and CAR T-cell therapies — work by targeting broader disease processes rather than single molecules. PDGrapher aims to expand this concept by identifying drug targets that can reverse signs of disease, even when the precise molecular mechanisms are not yet fully understood.
How PDGrapher works: Mapping complex cellular networks
PDGrapher is based on a graph neural network — a form of AI that analyses not only individual data points but also the relationships and interactions between them. In biological research, this means mapping how genes, proteins, and signalling pathways influence one another inside a cell.
Instead of screening thousands of compounds blindly, PDGrapher simulates what would happen if certain genes or pathways were switched off, dialled down, or targeted with a drug. It then predicts whether these interventions would shift a diseased cell towards a healthier state.
“Instead of testing every possible recipe, PDGrapher asks: ‘Which mix of ingredients will turn this bland or overly salty dish into a perfectly balanced meal?’” said Zitnik.
Testing and validation: Proving its predictive power
To train the model, researchers fed PDGrapher a dataset of diseased cells both before and after treatment, allowing it to learn which gene changes led to recovery.
They then evaluated the tool using 19 independent datasets across 11 cancer types, combining both genetic and drug-based experiments. PDGrapher was asked to propose treatment options for samples and cancer types it had never seen before.
The model accurately predicted known drug targets that had been deliberately excluded during training and identified new candidates supported by emerging evidence. Notably, it highlighted KDR (VEGFR2) as a target for non-small cell lung cancer, consistent with clinical findings, and identified TOP2A, an enzyme already targeted by chemotherapy, as a promising target for preventing metastasis in certain tumours.
PDGrapher consistently outperformed comparable AI models — ranking correct therapeutic targets up to 35 percent higher and producing results up to 25 times faster.
Implications for future drug discovery
By focusing on targets that directly reverse disease traits, PDGrapher streamlines the drug discovery process. This allows researchers to prioritise fewer, more promising interventions and to design experiments that are faster and more cost-effective.
This capability is particularly valuable for complex diseases such as cancer, where tumours often evade therapies that strike only one target. Because PDGrapher identifies multiple disease drivers, it offers a way to design combination treatments that could prevent drug resistance.
In the future, with further validation, PDGrapher could be applied to individual patients’ cellular profiles to create personalised treatment strategies.
Broader applications and ongoing research
Beyond cancer, the research team is using PDGrapher to investigate neurological conditions such as Parkinson’s disease and Alzheimer’s disease, aiming to identify genetic drivers that could restore neuronal health.
They are also collaborating with Massachusetts General Hospital’s Center for X-linked Dystonia-Parkinsonism (XDP) to map potential drug targets for this rare, inherited neurodegenerative disorder.
“Our ultimate goal is to create a clear road map of possible ways to reverse disease at the cellular level,” Zitnik stated.
Read More